Evidence map›Paper›PMID 31322215›Full record

ArticleMolecular medicine reports2019

Protective effect of ISO‑1 against advanced glycation end product aggravation of PC12 cell injury induced by Aβ1‑40.

Ming Yu, Demei Zang, Yuhao Xu, Jie Meng, Shengnan Qian

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. MIF contribution to progressive brain diseases.Journal of neuroinflammation · 2024
    Review
  2. Dualistic roles and mechanistic insights of macrophage migration inhibitory factor in brain injury and neurodegenerative diseases.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
  3. Review
  4. Codonopsis pilosula Polysaccharides Alleviate AβCurrent Alzheimer research · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ming YuDepartment of Neurology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Demei ZangSchool of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Yuhao XuDepartment of Neurology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Jie MengSchool of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Shengnan QianSchool of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Jiangsu University · CNAffiliated Hospital of Jiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced glycation end products (AGEs) are important pathogenic substances involved in diabetes mellitus (DM) and its complications. AGEs also serve important roles in promoting the development of Alzheimer's disease (AD). Macrophage migration inhibitory factor (MIF), an inflammatory stimulant and a pathogenic factor involved in DM, was previously reported to be present at increased levels in the cerebrospinal fluid of patients with AD and mild cognitive impairment compared with age‑matched healthy controls. By investigating the association between AGEs and MIF, and the effects of neuroinflammation on AD, the present study aimed to increase understanding of the specific molecular mechanisms involved in the pathogenesis of DM and AD, and the connection between these diseases. PC12 cells were cultured in vitro; the levels of MIF mRNA and protein were determined using reverse transcription‑quantitative (RT‑q)PCR and western blot analyses. The optimal concentrations of AGEs and amyloid β 1‑40 (Aβ1‑40) were also determined in the cell model of AD using Cell Counting Kit‑8 and MTT assays. Cell numbers and morphological changes were observed following the treatment of Aβ1‑40‑stimulated PC12 cells with AGEs and the MIF inhibitor (S,R)‑3‑(4‑hydroxyphenyl)‑4,5‑dihydro‑5‑isoxazole acetic acid methyl ester (ISO‑1). The mRNA expression levels of interleukin (IL)‑1β, IL‑6, tumor necrosis factor‑α (TNF‑α) and MIF were determined via RT‑qPCR analysis. The results showed that the levels of MIF mRNA and protein were significantly increased in cells treated with AGEs compared with the control group. In the AD model group, the inhibition of PC12 cell growth was significantly increased, and the mRNA expression levels of IL‑1β, IL‑6, TNF‑α and MIF were also increased. Compared with treatment with AGEs alone, the combination of AGEs treatment with ISO‑1 significantly improved the survival rate and resulted in the reduced expression of inflammatory mediators in the AD cell model. Thus, ISO‑1 reduced AGEs‑mediated damage in the AD cell model. This may be a consequence of AGEs‑mediated MIF expression promoting neuritis in the AD cell model, whereas ISO‑1 decreased the expression of neuroinflammatory mediators.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCell ProliferationCell SurvivalGlycation End Products, AdvancedIntramolecular OxidoreductasesIsoxazolesMacrophage Migration-Inhibitory FactorsPC12 CellsPeptide FragmentsProtective AgentsRats3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl esterAmyloid beta-Peptidesamyloid beta-protein (1-40)Glycation End Products, AdvancedIntramolecular OxidoreductasesIsoxazolesMacrophage Migration-Inhibitory FactorsMif protein, ratPeptide FragmentsProtective Agents

Identifiers

PMID31322215
PMCPMC6691208
OpenAlexW2958536092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.